Brokerages Set Genmab A/S (NASDAQ:GMAB) PT at $45.20

Shares of Genmab A/S (NASDAQ:GMAB) have been assigned an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $45.20.

GMAB has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Wednesday, October 16th. Redburn Atlantic began coverage on Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th. Truist Financial decreased their price target on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a report on Monday, September 9th. Finally, Morgan Stanley restated an “equal weight” rating and set a $31.00 price target on shares of Genmab A/S in a report on Wednesday, September 11th.

Hedge Funds Weigh In On Genmab A/S

Several large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. lifted its holdings in shares of Genmab A/S by 137.7% during the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after buying an additional 544 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Genmab A/S by 123.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 3,240 shares of the company’s stock valued at $81,000 after purchasing an additional 1,787 shares during the period. Blue Trust Inc. grew its position in Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after purchasing an additional 3,880 shares during the last quarter. Headlands Technologies LLC raised its position in shares of Genmab A/S by 1,702.8% during the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after buying an additional 4,853 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. grew its position in Genmab A/S by 7.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after buying an additional 478 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Stock Up 2.5 %

Shares of GMAB stock opened at $21.16 on Monday. The stock has a 50-day simple moving average of $22.83 and a 200 day simple moving average of $25.72. The stock has a market capitalization of $14.00 billion, a P/E ratio of 20.54, a P/E/G ratio of 0.65 and a beta of 0.99. Genmab A/S has a fifty-two week low of $20.34 and a fifty-two week high of $32.88.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). The business had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same period in the prior year, the firm earned $0.47 EPS. On average, sell-side analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.